Table 1 KRAS amplification and clinico-pathological characteristics
From: Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas
| Â | KRAS amplification | Â | ||||||
|---|---|---|---|---|---|---|---|---|
total (n = 470) | negative (n = 443) | positive (n = 27) |  | |||||
n | % | n | % | n | % | p-value | ||
sex | male | 295 | 62.8% | 275 | 58.5% | 20 | 4.3% | 0.528 |
female | 145 | 30.9% | 138 | 29.4% | 7 | 1.5% | ||
n.a. | 30 | 6.4% | 30 | 6.4% | 0 | 0.0% | Â | |
agegroup | < 50 | 42 | 8.9% | 41 | 8.7% | 1 | 0.2% | 0.339 |
> 50 | 331 | 70.4% | 305 | 64.9% | 26 | 5.5% | ||
not available | 97 | 20.6% | 97 | 20.6% | 0 | 0.0% | Â | |
tumor stage | T1 | 65 | 13.8% | 62 | 13.2% | 3 | 0.6% | 0.830 |
T2 | 147 | 31.3% | 136 | 28.9% | 11 | 2.3% | ||
T3 | 166 | 35.3% | 157 | 33.4% | 9 | 1.9% | ||
T4 | 67 | 14.3% | 63 | 13.4% | 4 | 0.9% | ||
not available | 25 | 5.3% | 25 | 5.3% | 0 | 0.0% | Â | |
nodal stage | N0 | 165 | 35.1% | 160 | 34.0% | 5 | 1.1% | 0.024 |
N1 | 105 | 22.3% | 100 | 21.3% | 5 | 1.1% | ||
N2 | 78 | 16.6% | 71 | 15.1% | 7 | 1.5% | ||
N3 | 76 | 16.2% | 66 | 14.0% | 10 | 2.1% | ||
not available | 46 | 9.8% | 46 | 9.8% | 0 | 0.0% | Â | |
localisation | proximal | 205 | 43.6% | 186 | 39.6% | 19 | 4.0% | 0.092 |
body | 70 | 14.9% | 69 | 14.7% | 1 | 0.2% | ||
distal | 98 | 20.9% | 91 | 19.4% | 7 | 1.5% | ||
| Â | not available | 97 | 20.6% | 97 | 20.6% | 0 | 0.0% | Â |